Patents by Inventor Martyn Brown
Martyn Brown has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11264614Abstract: The present invention relates to an energy storage device comprising a silicate comprises a formula: MvM1wM2xSiyOz where M is selected from the group consisting of Li, Na, K, Al, and Mg M1 is selected from the group consisting of alkaline metals, alkaline earth metals, Ti, Mn, Fe, La, Zr, Ce, Ta, Nb, V and combinations thereof; M2 is selected from the group consisting of B, Al, Ga, Ge or combinations thereof; v, y and z are greater than 0; w and/or x is greater than 0; y?x; and wherein MvM1wM2xSiyOz accounts for at least 90 wt % of the composition.Type: GrantFiled: January 31, 2019Date of Patent: March 1, 2022Assignee: Thermal Ceramics UK LimitedInventors: Martyn Brown, Richard Clark, Jason Peter Street
-
Publication number: 20190237765Abstract: The present invention relates to an energy storage device comprising a silicate comprises a formula: MvM1wM2xSiyOz where M is selected from the group consisting of Li, Na, K, Al, and Mg M1 is selected from the group consisting of alkaline metals, alkaline earth metals, Ti, Mn, Fe, La, Zr, Ce, Ta, Nb, V and combinations thereof; M2 is selected from the group consisting of B, Al, Ga, Ge or combinations thereof; v, y and z are greater than 0; w and/or x is greater than 0; y?x; and wherein MvM1wM2xSiyOz accounts for at least 90 wt % of the composition.Type: ApplicationFiled: January 31, 2019Publication date: August 1, 2019Inventors: Martyn BROWN, Richard CLARK, Jason Peter STREET
-
Patent number: 8822475Abstract: The present invention is directed to methods of use of a compound of Formula I: and/or a pharmaceutically-acceptable salt, hydrate, solvate, tautomer, optical isomer, or combination thereof, a composition comprising the thiosemicarbazone, a method of administration thereof, and use thereof to treat a cancer.Type: GrantFiled: February 19, 2013Date of Patent: September 2, 2014Assignee: Critical Outcome Technologies, Inc.Inventors: Wayne R. Danter, Martyn Brown, Franck LePifre
-
Patent number: 8420643Abstract: The present invention is directed to methods of use of a compound of Formula I: and/or a pharmaceutically-acceptable salt, hydrate, solvate, tautomer, optical isomer, or combination thereof, a composition comprising the thiosemicarbazone, a method of administration thereof, and use thereof to treat a cancer.Type: GrantFiled: December 2, 2011Date of Patent: April 16, 2013Assignee: Critical Outcome Technologies Inc.Inventors: Wayne R. Danter, Martyn Brown, Franck LePifre
-
Patent number: 8367675Abstract: The present invention is directed to methods of use of a compound of Formula I: and/or a pharmaceutically-acceptable salt, hydrate, solvate, tautomer, optical isomer, or combination thereof, a composition comprising the thiosemicarbazone, a method of administration thereof, and use thereof to treat a cancer.Type: GrantFiled: July 25, 2011Date of Patent: February 5, 2013Assignee: Critical Outcome Technologies Inc.Inventors: Wayne R. Danter, Martyn Brown, Franck LePifre
-
Patent number: 8258322Abstract: An improved process is provided for the synthesis of hexahydrodibenzo[b,d]pyran-9-ones, such as nabilone.Type: GrantFiled: August 28, 2009Date of Patent: September 4, 2012Assignee: Watson Laboratories, Inc.Inventors: Valeriy Mikaylo, Subakar Paramanantham, Ilya Avrutov, Martyn A. Brown, Zemin Li, Natalie Lazarowych
-
Patent number: 8252800Abstract: The present invention relates to compounds of the Formula I, the pharmaceutically acceptable salts and stereoisomers thereof, which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions in mammals: wherein n is an integer, preferably n is 1; wherein R1 and R2 are independently selected from the group consisting of:Type: GrantFiled: July 28, 2009Date of Patent: August 28, 2012Inventors: Wayne R. Danter, Martyn Brown, George Ma, Ghenadie Rusu, Jianhua Zhong, Natalie Lazarowych, Stephen Houldsworth
-
Publication number: 20120077820Abstract: The present invention is directed to methods of use of a compound of Formula I: and/or a pharmaceutically-acceptable salt, hydrate, solvate, tautomer, optical isomer, or combination thereof, a composition comprising the thiosemicarbazone, a method of administration thereof, and use thereof to treat a cancer.Type: ApplicationFiled: December 2, 2011Publication date: March 29, 2012Applicant: CRITICAL OUTCOME TECHNOLOGIES INC.Inventors: Wayne R. Danter, Martyn Brown, Franck LePifre
-
Publication number: 20110281887Abstract: The present invention is directed to methods of use of a compound of Formula I: and/or a pharmaceutically-acceptable salt, hydrate, solvate, tautomer, optical isomer, or combination thereof, a composition comprising the thiosemicarbazone, a method of administration thereof, and use thereof to treat a cancer.Type: ApplicationFiled: July 25, 2011Publication date: November 17, 2011Applicant: CRITICAL OUTCOME TECHNOLOGIES INC.Inventors: Wayne R. Danter, Martyn Brown, Franck LePifre
-
Patent number: 8034815Abstract: The present invention is directed to a compound of Formula I: and/or a pharmaceutically-acceptable salt, hydrate, solvate, tautomer, optical isomer, or combination thereof, a composition comprising the thiosemicarbazone, a method of administration thereof, and use thereof to treat a cancer.Type: GrantFiled: January 11, 2008Date of Patent: October 11, 2011Assignee: Critical Outcome Technologies, Inc.Inventors: Wayne R. Danter, Martyn Brown, Franck LePifre
-
Publication number: 20100056811Abstract: An improved process is provided for the synthesis of hexahydrodibenzo[b,d]pyran-9-ones, such as nabilone.Type: ApplicationFiled: August 28, 2009Publication date: March 4, 2010Inventors: Valeriy Mikaylo, Subakar Paramanantham, Ilya Avrutov, Martyn A. Brown, Zemin Li, Natalie Lazarowych
-
Patent number: 7629347Abstract: The present invention relates to uses of the compounds of Formula I as well as pharmaceutically acceptable salts and stereoisomers thereof in methods to treat a variety of tumors in mammals involving abnormal tyrosine kinase signaling, the compounds represented as: wherein R1 and R2 are independently selected from the group consisting of H; alkyl; alkenyl; alkynyl; halogen; aryl; heteroaryl containing N, O, or S; the aryl and heteroaryl may be further substituted with halogen, an alkyl, alkenyl, and alkynyl; NZ1Z2, wherein Z1 and Z2 are independently selected from the group consisting of H and alkyl; and (CO)Y wherein Y is selected from the group consisting of H, alkyl, alkenyl, alkynyl, aryl, heteroaryl containing N, O, or S, and the aryl and heteroaryl may be further substituted with halogen, alkyl, alkenyl, and alkynyl; with the proviso that when R1 is hydrogen, R2 is a group other than hydrogen.Type: GrantFiled: October 9, 2003Date of Patent: December 8, 2009Assignee: Critical Outcome Technologies, Inc.Inventors: Wayne R. Danter, George Ma, Natalie Lazarowych, Stephen Houldsworth, Martyn Brown, Ghenadie Rusu, Jianhua Zhong
-
Publication number: 20090298855Abstract: The present invention relates to compounds of the Formula I, the pharmaceutically acceptable salts and stereoisomers thereof, which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions in mammals: wherein n is an integer, preferably n is 1; wherein R1 and R2 are independently selected from the group consisting of:Type: ApplicationFiled: July 28, 2009Publication date: December 3, 2009Applicant: Critical Outcome Technologies Inc.Inventors: Wayne R. Danter, Martyn Brown, George Ma, Ghenadie Rusu, Jianhua Zhong, Natalie Lazarowych, Stephen Houldsworth
-
Patent number: 7585866Abstract: The present invention relates to compounds of the Formula I, the pharmaceutically acceptable salts and stereoisomers thereof, which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions in mammals: wherein n is an integer, preferably n is 1; wherein R1 and R2 are independently selected from the group consisting of:Type: GrantFiled: July 31, 2003Date of Patent: September 8, 2009Assignee: Critical Outcome Technologies, Inc.Inventors: Wayne R. Danter, Martyn Brown, George Ma, Ghenadie Rusu, Jianhua Zhong, Natalie Lazarowych, Stephen Houldsworth
-
Publication number: 20080171744Abstract: The present invention is directed to a compound of Formula I: and/or a pharmaceutically-acceptable salt, hydrate, solvate, tautomer, optical isomer, or combination thereof, a composition comprising the thiosemicarbazone, a method of administration thereof, and use thereof to treat a cancer.Type: ApplicationFiled: January 11, 2008Publication date: July 17, 2008Applicant: 6441513 CANADA INC.Inventors: Wayne R. Danter, Martyn Brown, Franck LePifre
-
Publication number: 20060111371Abstract: The present invention relates to uses of the compounds of Formula I as well as pharmaceutically acceptable salts and stereoisomers thereof in methods to treat a variety of tumors in mammals involving abnormal tyrosine kinase signalling, the compounds represented as: wherein R1 and R2 are independently selected from the group consisting of H; alkyl; alkenyl; alkynyl; halogen; aryl; heteroaryl containing N, O, or S; the aryl and heteroaryl may be further substituted with halogen, an alkyl, alkenyl, and alkynyl; NZ1Z2, wherein Z1 and Z2 are independently selected from the group consisting of H and alkyl; and (CO)Y wherein Y is selected from the group consisting of H, alkyl, alkenyl, alkynyl, aryl, heteroaryl containing N, O, or S, and the aryl and heteroaryl may be further substituted with halogen, alkyl, alkenyl, and alkynyl; with the proviso that when R1 is hydrogen, R2 is a group other than hydrogen.Type: ApplicationFiled: October 9, 2003Publication date: May 25, 2006Inventors: Wayne Danter, George Ma, Natalie Lazarowych, Stephen Houldsworth, Martyn Brown, Ghenadie Rusu, Jianhua Zhong
-
Publication number: 20060069105Abstract: The present invention relates to compounds of the Formula I, the pharmaceutically acceptable salts and stereoisomers thereof, which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions in mammals: wherein n is an integer, preferably n is 1; wherein R1 and R2 are independently selected from the group consisting of:Type: ApplicationFiled: July 31, 2003Publication date: March 30, 2006Inventors: Wayne Danter, Martyn Brown, George Ma, Ghenadie Rusu, Jianhua Zhong, Natalie Lazarowych, Stepehn Houldsworth